MD Anderson & Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development; Translational Research Will Focus on Advancing Therapeutic Strategies for Potent & Selective CDK2 Inhibitor Across Broad Range of Tumor Types

On July 28, 2021, The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation announced a three-year strategic research collaboration focused on accelerating development of BLU-222, an investigational precision cancer therapy designed to target cyclin-dependent kinase 2 (CDK2) (image), a critical cell-cycle regulator. The collaboration brings together MD Anderson translational research scientists, the drug development capabilities of MD Anderson’s Therapeutics Discovery division, and Blueprint Medicines’ precision therapy pipeline and expertise. The teams seek to characterize the range of cancer types susceptible to treatment with a selective CDK2 inhibitor, advance BLU-222 mono- and combination-therapy strategies with the potential to maximize patient benefit, and identify novel biomarkers that may better predict treatment response and optimize patient selection.

Login Or Register To Read Full Story